Transfusion Threshold of Hemoglobin 80 g/L Is Comparable to 100 g/L in Terms of Bleeding in Cardiac Surgery : A Prospective Randomized Study by Laine, Antti et al.






















ss: anttTransfusion Threshold of Hemoglobin 80 g/L Is
Comparable to 100 g/L in Terms of Bleeding in
Cardiac Surgery: A Prospective Randomized Study
Antti Laine, MD1, Tomi Niemi, MD, PhD,
Alexey Schramko, MD, PhD
Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of
Helsinki, Helsinki University Hospital, Helsinki, FinlandObjective: Anemia is common after cardiac surgery and, according to some suggestive evidence, may be associated with increased bleeding,
other morbidity, and mortality. However, transfusion of red blood cells (RBC) may cause adverse effects and increase cost. The authors
hypothesized that the restrictive hemoglobin threshold (Hb of 80 g/L) may aggravate bleeding more than the higher Hb threshold (Hb 100 g/L).
Design: Prospective randomized trial.
Type of Hospital: University Hospital of Helsinki, Finland.
Participants: Eighty patients with written informed consent, scheduled for elective open-heart surgery were randomized in 2 groups.
Interventions: Two study groups had RBC transfusion threshold of either Hb 80 g/L or 100 g/L. These triggers were followed for a 24-hour
period postoperatively. A medical follow-up was carried out for 7 days after surgery.
Measurements and Main Results: Rotational thromboelastometry (ROTEM) and conventional laboratory tests were performed to evaluate
coagulation. There was no significant difference in bleeding or ROTEM parameters between the groups. Complication rate and Hb concentration
after 7-day follow-up were not different between the groups, but Group 100 g/L had received twice the amount of RBC transfusions.
Conclusion: Hb threshold of 80 g/L for RBC transfusion in cardiac surgery is comparable to 100 g/L in terms of bleeding and possibly short-
term complications.
& 2018 Elsevier Inc. All rights reserved.
Key Words: cardiac surgery; transfusion, bleedingHEMOGLOBIN (Hb) has a crucial role in carrying oxygen
to tissues. Evidence supports that red blood cells (RBCs) play
an active role in hemostasis.1 Anemia is common during and/j.jvca.2017.08.039
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i.laine@hus.fi (A. Laine).after cardiac surgery, and it is associated with increases in
morbidity and mortality.2–4 Transfusion of allogeneic RBC is
typically the treatment of choice. Cardiac surgery has one of
the highest associated transfusion rates with over 50% of
patients receiving transfusions.5 On the other hand, transfusion
of RBC, or other blood components, is associated with
numerous harmful effects, such as infection, acute kidney
injury, ischemic events, prolonged hospital stay, increased
early and late mortality, and hospital costs.2,6–8
A recent guideline from the AABB recommends restrictive
transfusion strategy in most clinical settings, including cardiac
surgery.9 The results of trials studying critically ill patients (ie,
TRICC [Transfusion Requirements in Critical Care] or TRISS
A. Laine et al. / Journal of Cardiothoracic and Vascular Anesthesia 32 (2018) 132–140 133[Transfusion Requirements in Septic Shock]) also support the
idea of lower transfusion thresholds because there was no
significant difference in 30- and 90-day mortality when
comparing higher (Hb 90 g/L) versus lower (Hb 70 g/L)
transfusion thresholds.10,11 However, particularly in cardiac
surgery,12–14 recent studies have conflicting results regarding
restrictive transfusion strategies, and no clear consensus exists.
Transfusion thresholds in cardiac surgery have generally
been more liberal in clinical practice, partly due to justified
concern of cardiac ischemia, bleeding, and other undesired
sequelae.
It has been shown that lower hematocrit (Hct) influences
coagulation in vivo.15 Rotational thromboelastometry
(ROTEM), a point-of-care whole blood coagulation test, gives
more rapid and detailed information about patients’ coagula-
tion status, compared with conventional laboratory tests
performed with cell free plasma.16,17 The use of ROTEM-
guided transfusion protocols also has been shown to reduce the
need for transfusions in cardiac surgery.18
The aim of this prospective randomized study was to
compare the effect of 2 different RBC transfusion thresholds
(80 g/L v 100 g/L) perioperatively on bleeding and coagulation
parameters measured by ROTEM in cardiac surgical patients.Methods
After registering the study at the Hospital District of
Helsinki and Uusimaa (§94,9.05.2014) and receiving approval
from the institutional Ethics Committee for Surgery in
Helsinki University Hospital 2014 (D-number 58/13/03/02/
2014), the authors gathered 80 patients scheduled for non-
emergency coronary artery bypass grafting (CABG), simple
one valve (aortic or mitral) replacement or both, requiring
cardiopulmonary bypass (CPB). Patients were operated on
between June 2014 and December 2015. Exclusion criteria
included any hereditary or acquired hemostatic disorders, any
malignancies, and severe chronic kidney disease (glomerular
filtration rate o30 mL/min). Patients’ medical history and severity
of the surgery was described with European System for Cardiac
Operative Risk Evaluation, (numeric) EuroSCORE I.19
After providing written informed consent, patients were
randomized in 2 groups: (1) “Group 80,” RBC transfusion
threshold of 80 g/L, and (2) “Group 100,” RBC transfusion
threshold of 100 g/L. Randomization was done in blocks of 20
patients and using closed envelopes (Fig 5). Use of other blood
components and medications was left to clinicians’ discretion
and based on Helsinki University Hospital treatment protocols;
that is, if postoperative bleeding is severe (4200 mL/h),
activated coagulation time (ACT, s), thromboplastin time
value (TT, %), and platelet count (PLC) are measured. If
ACT is prolonged more than 10 seconds compared with pre-
bypass level, 25 mg of protamine is administered. Pooled
human plasma (5 mL/kg) is given if TT is o50% and
platelets (1 U/10 kg) transfused if PLC is o50  109/L. If
bleeding continues, 1 g of tranexamic acid is administered.
Intervention started at the beginning of surgery, and it lasted24 hours. The study was unblinded due to the Finnish practice
of anesthetists performing transfusions themselves.
Patients’ own medication was continued until surgery
according to hospital protocol. Patients did not receive any
low molecular weight heparin for 24 hours before surgery. The
possible acetylsalicylic acid treatment was continued until
surgery, but the cessation of oral anticoagulation was per-
formed according to the hospital protocol: Warfarin 3 days and
new oral anticoagulants 5 days preoperatively. Patients
received a 1-g bolus of tranexamic acid during anesthesia
induction. CPB was performed according to institutional
standards described elsewhere.20 Before cannulation a bolus
of heparin (300-400 IU/kg body weight) was administered.
Another 1 to 2 g bolus of tranexamic acid also was
administered in the CPB routinely. Intraoperatively ACT was
measured repeatedly to monitor the efficiency of anticoagula-
tion. In the case of ACT o480 s, a further bolus of heparin
was administered. After finishing the CPB, heparin was
antagonized with protamine sulfate administered at 1 mg to
100 IU ratio to initial dose of heparin.
Conventional laboratory tests were performed preopera-
tively and at predetermined time intervals. During surgery
and postoperative intensive care, Hb concentrations were
monitored hourly during surgery, every 30 minutes during
CPB, and every 2 to 3 hours in the intensive care unit (ICU),
or more frequently, if needed. If Hb level was 79 g/L or less,
99 g/L or less, respectively, the patient received 1 unit of
packed RBC, and Hb was measured again. Transfusions were
carried out until Hb level reached 80 g/L or more, 100 g/L or
more, respectively. Cell salvage was used only in few isolated
cases, as procedures were estimated to be simple and patients
did not have predisposing risk factors for extensive bleeding.
ROTEM (TEM International GmbH, Munich, Germany)
was performed at 3 predetermined time points: before anesthe-
sia induction, immediately after CPB/surgery, and on the first
postoperative morning. Tissue factor with (FibTEM) or with-
out (ExTEM) cytochalasin D was used for coagulation
activation. In FibTEM, platelet function is inhibited comple-
tely, therefore it is possible to measure the isolated effect of
fibrinogen on blood coagulation. The following variables were
recorded: clotting time (CT, s), clot formation time (CFT, s),
maximum rise in clot firmness (given as the angle α),
maximum clot firmness (MCF, mm), and clot lysis after 30
minutes. The clinical staff was blinded to the ROTEM data.
Other data collected during the study period were the amount
of bleeding during the surgery (estimate done by surgeons/
anesthetists) and postoperatively from the chest tubes, RBC
and blood product transfusions, diuresis, and cumulative fluid
balance. Patient data during the surgery and intensive care
were collected with PI Client Information System (Caresuite
8.2, PiCIS Inc, San Francisco, CA).Statistical Analysis
Based on results of the authors’ previous study,21 the group
size was calculated with power (1-β) ¼ 80% and α ¼ 0.05
A. Laine et al. / Journal of Cardiothoracic and Vascular Anesthesia 32 (2018) 132–140134assuming that Group 100 would have 25% less bleeding than
Group 80.
The differences were analyzed with the nonparametric
repeated measures analysis of variance (Kruskal-Wallis test).
Correlations were tested with the Spearman test. Mann-
Whitney U test was used for paired comparisons. Because
the data was mostly not normally distributed (Kolmogorov-
Smirnov test), results are shown as medians (interquartile
range, IQR). The results of normally distributed parameters are
shown as mean values with 95% confidence intervals (CIs).
Significance is developed at p values less than 0.05. Statistical
analysis was performed with SPSS 22.0 for MAC (SPSS Inc,
Chicago, IL).
Results
Eighty non-emergency cardiac surgery patients were
included in the study; 40 patients were randomized in each
group. All 80 patients were included in the analyses. Char-
acteristics of the patients were fairly similar between the both
groups, with the exception of the patients in Group 80 being
older (70.5 v 64.5, p ¼ 0.023) and having a higher Euro-
SCORE (6.13 v 4.30, p ¼ 0.007) (Table 1).
In the Group 80, mean Hb (95% CI) concentration right
after initiating CPB was 88.9 g/L (83.5–94.3 g/L) and after
weaning from CPB 98.4 g/L (94.8–102.1 g/L). In the Group
100, Hb after initiating CPB was 90.7 g/L (86.8–94.5 g/L) and
after weaning from CPB 106.4 g/L (104.3–108.4 g/L).
Although no statistically significant difference between the
groups in mean Hb was observed before surgery, it developed
into statistical significance during CPB (see Fig 1). Difference
between the groups remained statistically significant until the
first postoperative day (POD). Seven days after surgery

















Days till discharge to secondary ward*
Abbreviations: AVR, aortic valve replacement; BMI, body mass index; CABG, co
replacement; OR, operating room.
Median values (unless marked * for mean value), interquartile range/95% confiden
p Value determined with Mann-Whitney U test.(100 g/L v 104 g/L, p ¼ 0.722). In both groups, Hb values
preoperatively were significantly higher than in the operating
room (OR), ICU, or 7 days postoperatively (p o 0.001).
Thirty-five percent of patients in Group 80 had at least 1 Hb
measurement under 80 g/L during the entire CPB, 84% of
patients in Group 100 had at least 1 Hb measurement under
100 g/L, respectively. After CPB, numbers were 6% and 16%,
respectively (Table 4).
Between study groups, there was no significant difference in
intraoperative or postoperative bleeding. In Group 80, mean
(95% CI) blood loss in the OR was 433 mL (356–510 mL) and
in the ICU 680 mL (551–808 mL). In Group 100, the blood
loss was 427 mL (95% CI 365–489 mL) in the OR and 618
mL (95% CI 532–703 mL) in the ICU. Patients in Group 100
were given significantly more RBC transfusions in the OR (2.0
U v 0.9 U, p ¼ 0.001), but not in the ICU (0.3 v 0.4 U, p ¼
0.542). Amount of other transfused blood products (pooled
human plasma or platelets) showed no significant differences
between the groups, p 4 0.05. Finnish RBC unit equals
approximately 250 mL, pooled human plasma unit 200 mL
and platelet unit 200 mL.
Mean ROTEM parameters were within normal ranges in
both groups during the entire study period. The MCF, CT,
CFT, and α-angle in ExTEM and FibTEM showed no
significant differences between the groups. No excessive lysis
of the clot was observed in any of the cases (Figs 2–4).
Preoperative conventional laboratory results showed no
signs of hyper- or hypocoagulation, median values were in
the reference range (Table 2). There were no significant
differences in these analyses between the groups.
Preoperative PLC was positively correlated with preopera-
tive ExTEM (p o 0.001) and FibTEM MCF (p ¼ 0.016).
Preoperative Hct was negatively correlated with preoperative
ExTEM (p o 0.001) and FibTEM MCF (p ¼ 0.004).Group 80 Group 100 p Value
29 (72.5) 28 (70.0)
11 (37.5) 12 (30.0)
70.5 (67.8-73.2) 64.5 (60.6-68.3) 0.023
26.7 (4.8) 28.4 (8.6) 0.245
6 (4) 4 (4) 0.007
28 (70) 29 (72.5)
5 (12.5) 3 (7.5)
4 (10) 7 (17.5)
1 (2.5) 0 (0)
2 (5) 1 (2.5)
21 (52.5%) 18 (45%)
19 (47.5%) 22 (55%)
96.5 (38.3) 96.5 (41.5) 0.912
73.0 (31.3) 76.0 (37.3) 0.996
1.88 (1.37-2.38) 1.47 (1.09-1.85) 0.120
ronary artery bypass graft; CPB, cardiopulmonary bypass; MVR, mitral valve
ce interval in parentheses.
Fig 1. Mean hemoglobin during the study period at various time points. *Statistically significant differences. CPB, cardiopulmonary bypass; ICU, intensive care
unit; POD, postoperative day.
A. Laine et al. / Journal of Cardiothoracic and Vascular Anesthesia 32 (2018) 132–140 135Preoperative PLC was associated with the subsequent ROTEM
analyses during the perioperative period as well; p values for
correlations between preoperative PLC and post-CBP ExTEMFig 2. ExTEM clotting time (mean) on predeterminedwere 0.003, FibTEM 0.002, and POD 1 ExTEM 0.001,
FibTEM 0.048. There were no significant ROTEM changes
in individual patients during the course of the study period.time points. Reference range shown with red lines.
Fig 3. ExTEM maximum clot firmness (mean) on predetermined time points. Red dotted lines represent reference range.
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the first 24 hours after surgery on 2 patients in each group.
These patients had preoperatively significantly lower Hb (113
v 135 g/L, p ¼ 0.004) and Hct (34.5 v 40.0, p o 0.001) in
comparison with other study patients. Their ROTEM-para-
meters, Hb during surgery and postoperatively, PLC, activatedFig 4. FibTEM maximum clot firmness (mean) on predeterminpartial thromboplastin time (aPTT), and TT did not differ
significantly from other patients. Only 1 major thrombotic
complication was recorded: 1 patient in Group 80 with a
CABG operation had postoperative myocardial infarction with
ST-elevation. In this particular patient, there was no sign of
hypercoagulation in the laboratory analyses. The creatinineed time points. Red dotted lines represent reference range.
Table 2
Laboratory Tests at Predetermined Time Points During the Study (Preoperative Unless Stated Otherwise)
Lab Test Ref. Range Group 80 Group 100 p Value*
Hb (g/L) (134-167 [men], 117-155 [women]) 137 (25) 136.5 (19) 0.600
Hb 1 week (134-167 [men], 117-155 [women]) 100 (20) 104 (16) 0.722
Hct (%) (35-46 [men], 39-50 [women]) 40 (5.5) 40 (5.3) 0.527
PLC ( 109/L) (150-360) 222 (115) 209 (88) 0.829
APTT, s (23-33) 28 (5) 28 (2) 0.334
TT, n (%) (70-30) 94 (26) 87 (19) 0.943
INR 1.0 (0.1) 1.1 (0.1) 0.456
Creatinine, mmol/L (60-100 [men], 50-90 [women]) 87 (26) 81 (32) 0.502
Creatinine POD 1 (60-100 [men], 50-90 [women]) 82.5 (34) 79.5 (41) 0.411
Creatinine 1 week (60-100 [men], 50-90 [women]) 91.5 (30)† 90 (47)† 0.248
CK-MBm‡ (0-7 mg/L) 18 (13) 15.5 (11) 0.199
Abbreviations: APTT, activated partial thromboplastin time; CK-MBm, creatinine kinase MB-mass; Hb, hemoglobin; Hct, hematocrit; PLC, platelet count; POD,
postoperative day; TT, thromboplastin time.
Values are medians (interquartile range in parentheses).
np Value determined with Mann-Whitney U test.
†Highest measured value during 7-day follow-up.
‡CK-MBm on POD 1.
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the reference value of CK-MBm on POD 1 in both groups
as values remained under 50 mg/L in all except the 1 patientFig 5. Patient enrollmsuffering myocardial infarction with ST-elevation (CK-MBm
reaching peak value of 119 mg/L). The difference in
median CK-MBm between groups was not statisticallyent flow diagram.
Table 3
Transfusions, Bleeding, and Fluid Balance
Group Hb 480 g/L Group Hb 4100 g/L p Value (t test)
RBC, U OR 0.90 (0.47-1.33) 1.98 (1.52-2.43) 0.001
POD 1 0.38 (0.05-0.70) 0.25 (-0.01 to 0.51) 0.542
7-day 0.45 (0.19-0.71) 0.38 (0.03-0.72) 0.727
Plasma, U OR 0.18 (-0.07 to 0.42) 0.20 (-0.08 to 0.48) 0.894
POD 1 0.20 (-0.12 to 0.52) 0.05 (-0.05 to 0.15) 0.367
7-day 0.03 (-0.03 to 0.08) 0 0.323
Platelets, U OR 0.80 (-0.13 to 1.73) 1.40 (0.19-2.61) 0.429
POD 1 1.20 (0.07-2.33) 0.90 (-0.16 to 1.96) 0.697
7-day 0 0
Albumin, g OR 12.5 (5.63-19.37) 8.0 (1.94-14.06) 0.324
POD 1 21.10 (16.04-26.16) 17.50 (11.63-23.37) 0.350
Bleeding, mL OR 433.3 (356.6-510.1) 427.1 (365.3-488.9) 0.899
POD 1 679.6 (551-808.5) 618.0 (532.8-703.2) 0.422
Fluid balance, mL POD 1 3,948.4 (3,509.0-4,387.8) 3,399.2 (-2,839.6 to 3,958.7) 0.123
Diuresis, mL POD 1 2,035.8 (1,793.0-2,278.6) 2,072.6 (1,843.6-2,301.6) 0.824
Abbreviations: OR, operating room; Plasma, pooled human plasma, Octaplas; RBC, red blood cells; POD, postoperative day; 7-day, week long follow-up.
Mean values, 95% CI in parentheses.
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p 4 0.05).
Plasma creatinine values were not significantly different
between the groups: preoperatively 88.9 v 87.3 mmol/L (p ¼
0.775), on POD 1 86.9 v 83.2 mmol/L (p ¼ 0.548), and the
peak value during the 7-day period postoperatively was 105.8
v 96.4 mmol/L (p ¼ 0.276). In both groups elevation of
creatinine to the peak value was significant (p ¼ 0.001 and
p ¼ 0.003, respectively). The cumulative urine output (2,036
v 2,073 mL) and fluid balance (þ3,948 v þ3,399 mL) were
not significantly different between the groups (p ¼ 0.824 and
p ¼ 0.123, respectively; Table 3).Discussion
In this study, the authors showed that there was no
significant difference in blood loss or blood coagulation
related to open cardiac surgery when transfusion threshold
was either Hb value of 80 g/L or 100 g/L. The Hct value did
not correlate with any of the thromboelastometry or coagula-
tion parameters. Therefore, it seems that higher Hct may not
decrease the risk of bleeding or coagulation disturbance in
patients undergoing open-heart surgery. This study outcome isTable 4
Percentage (%) of Patients in Various Hb Categories During the Study
CPB After CPB
o80 g/L 80–100 g/L 4100 g/L o80 g/L 80–100 g/L 4100
Group 80 35.3 44.1 20.6 5.7 42.9 51.4
Group 100 18.9 64.9 16.2 0 16.2 83.8
Abbreviations: CPB, cardiopulmonary bypass; ICU, intensive care unit; POD, pos
The time intervals are CPB (during and after), ICU (during first 12 h in the ICU)consistent with previous reports and latest guidelines of
transfusion thresholds in cardiac surgery patients. The effect
of Hb value or RBC transfusion on bleeding or coagulation is
unclear. The previous studies have shown variable results in
cardiac or general surgery.13,14
The amount of blood loss in the current study was relatively
small, and no significant disturbances in coagulation were
observed. Although, Group 100 did receive twice the amount
of RBCs compared with Group 80 during the first POD, and
the mean Hb concentration in both groups remained higher
than 100 g/L during the first POD, even with the transfusion
thresholds defined as described. Furthermore, patients’ pre-
operative Hb values were in or close to the normal laboratory
reference range, and the relatively small amount of blood loss,
as well as accurate perioperative fluid therapy, did not lower
the Hb values to reach lower transfusion threshold in
numerous cases. Standardized priming volume of 1,000 to
1,500 mL Ringer’s Acetate (with 5,000 IU heparin) for the
CPB also did not produce clinically significant hemodilution.
Finally, the authors’ study protocol in Group 100 may increase
the treatment costs and predispose patients to transfusion-
related adverse effects without any clinical impact on bleeding
or coagulation. One week after surgery, the Hb difference
between the groups was lost. There was no significantICU first 12 h POD 1
g/L o80 g/L 80–100 g/L 4100 g/L o80 g/L 80–100 g/L 4100 g/L
0 30.0 70.0 0 47.5 52.5
0 10.0 90.0 0 5.0 95.0
toperative day.
, and POD 1.
A. Laine et al. / Journal of Cardiothoracic and Vascular Anesthesia 32 (2018) 132–140 139difference between transfusions during this 7-day period
postoperatively.
Murphy et al reported nonsuperiority of lower Hb thresh-
old,13 but the authors were unable to show actual benefits of
higher threshold as well. On the other hand, Reeves et al were
able to draw the conclusion that cost-wise lower hemoglobin
threshold would be superior without causing any additional
morbidity.14 These findings underline the need to further re-
evaluate the practices of liberal transfusions.
In this study, ROTEM analysis did not show any significant
differences between study groups. Clot formation and clot
strength were similar in both groups, which reflects well the
fact that clinical tendency to bleed did not differ between the
groups. This might be explained by higher than aimed Hb
levels. It has been shown before that clot strength reduces
when using hydroxyethyl starch (HES)-based colloids,21,22
and after abandoning HES solutions in surgical fluid manage-
ment in the authors’ institution, albumin (4% and 20%
solutions) is the only choice of colloid. This in addition to
the authors’ patients’ lack of underlying coagulation distur-
bances ensure proper clotting during perioperative period.
Platelet count was associated with more firm clots (higher
MCF) in the ROTEM analysis, as expected. FibTEM measures
specifically the effect of fibrinogen, RBC, and factor XIII on
the clot formation, and positive correlation of platelets with
FibTEM MCF might be explained with complex effect of
platelets and their mediators in coagulation even without
platelet adhesion. It has been shown that platelet blocking
with acetylsalicylic acid or clopidogrel does not block the
formation of thrombin.23 It was rather surprising to observe
that lower Hct was associated with thicker clots preoperatively
in the present study. Similar findings have actually been
demonstrated with ROTEM CT-parameter already in vitro
by Iselin et al24 and Spiezia et al,25 as well as in vivo with
TEG MA-parameter by Roeloffzen et al.1 In their experimental
studies, the observation was speculated to be attributed to the
test method itself. In fact, the test in these situations is more
sensitive to the total amount of clotting factors rather than the
concentration of cell surfaces or manufacturing process and
storage of RBC. However, authors assumed that this finding
may not have significant clinical relevance.
Patients enrolled in this study were scheduled for non-
emergency surgery, but had higher EuroSCORE values than
most of the usual elective cardiac surgery patients, in the
authors’ experience. Data collected previously in the authors’
institution showed mean EuroSCORE in 428 non-emergency
CABG patients to be 2.2 and in 220 other cardiac surgery
patients to be 2.6.26 Patients’ mean age was rather high,
especially in Group 80 as the difference was statistically
significant. Older age is known to predispose to complications
and delayed recovery.27 Nevertheless, this group managed as
well as did Group 100 regarding measured parameters and
complications.
The creatinine concentration behaved as expected with
modest rise after surgery and CPB. Urine output remained
normal and fluid balance moderately positive throughout the
first perioperative day. Lack of differences between groups inthese parameters did not reflect the relative abundance of
transfusions in Group 100. Despite that perioperative cardiac
ischemia has been a major concern throughout the years and
has perhaps led to extensive transfusions during cardiac
surgery, this study implies that lower transfusion threshold
(80 g/L) might not aggravate the incidence of cardiac
ischemia.
One of the strengths of this prospective randomized study is
the fair similarity of the preoperative laboratory values
between the groups. Adherence to study protocol is evident
when viewing the individual Hb measurements and percentage
of patients in the Hb range at certain time points. Complete
blinding regarding the transfusion was not possible due to the
study setup, but as mentioned before, clinicians were blinded
to the ROTEM measurements. There are also several limita-
tions to this study: between the groups, there is some
difference in age and EuroSCORE values, and cell salvage
was not regularly used. Most importantly, the authors were
unable to reach the lower transfusion threshold in the majority
of patients as lowest mean Hb values in both groups remained
closer to 90 g/L. Power was calculated with suggested
reduction of 25% in bleeding based on the authors’ previous
study, but effective mean blood loss was only about half of the
previous study.Conclusion
This study showed no significant effect of transfusion
thresholds of Hb 80 g/L and 100 g/L in terms of bleeding
and ROTEM coagulation parameters. It also seems that there
might not be any difference considering safety of the
2 different thresholds. Less transfusion means less risk of
transfusion-related adverse events and cost savings. Further
studies to clarify optimal Hb threshold in cardiac surgery are
needed.Acknowledgments
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